C06OD036029
Project Grant
Overview
Grant Description
UNC BSL3 Core Facility - Project Summary / Abstract:
The central goal of this project is to construct a 10,000 square feet Biosafety Level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in communities that lack access to health care.
UNC programs will soon exceed current infrastructure capacity due to increased demand. A strategic review of our microbial pathogenesis and infectious disease community concluded that urgent action was essential to support the high containment programs. Among the barriers to the growth of research was a lack of access to critical technologies and animal space within the existing BSL3 laboratories.
This transformative BSL3 core facility will allow UNC to expand to meet current and projected research needs in the UNC School of Medicine, School of Pharmacy, and Gillings School of Global Public Health. UNC has engaged multiple stakeholders across the research community to design and construct a centralized BSL3 suite to characterize the immune responses to coronavirus and other emerging viral pathogens and learn about what drives immune response, disease progression, and protection against future infection.
The proposal will attain four objectives:
1. Design and construct a high containment facility to bring investigators working on emerging and re-emerging infections together.
2. Enable access to specialized instrumentation including aerobiology and imaging equipment for supporting high containment research.
3. Create institution-wide core space to allow recruitment of new investigators to the infectious disease research community by increasing usable laboratory space in the BSL3 facility and purchasing new equipment that will serve investigators within the many UNC centers, institutes, and departments and their nationwide collaborators.
4. Enhance UNC's ability to lead the rapid response generating new therapeutics and vaccines to save lives on a local, national, and even global level.
The central goal of this project is to construct a 10,000 square feet Biosafety Level 3 (BSL3) research laboratory core facility to promote readiness to respond to future pandemics. Infectious diseases pose a severe and increasing threat to human health, especially in communities that lack access to health care.
UNC programs will soon exceed current infrastructure capacity due to increased demand. A strategic review of our microbial pathogenesis and infectious disease community concluded that urgent action was essential to support the high containment programs. Among the barriers to the growth of research was a lack of access to critical technologies and animal space within the existing BSL3 laboratories.
This transformative BSL3 core facility will allow UNC to expand to meet current and projected research needs in the UNC School of Medicine, School of Pharmacy, and Gillings School of Global Public Health. UNC has engaged multiple stakeholders across the research community to design and construct a centralized BSL3 suite to characterize the immune responses to coronavirus and other emerging viral pathogens and learn about what drives immune response, disease progression, and protection against future infection.
The proposal will attain four objectives:
1. Design and construct a high containment facility to bring investigators working on emerging and re-emerging infections together.
2. Enable access to specialized instrumentation including aerobiology and imaging equipment for supporting high containment research.
3. Create institution-wide core space to allow recruitment of new investigators to the infectious disease research community by increasing usable laboratory space in the BSL3 facility and purchasing new equipment that will serve investigators within the many UNC centers, institutes, and departments and their nationwide collaborators.
4. Enhance UNC's ability to lead the rapid response generating new therapeutics and vaccines to save lives on a local, national, and even global level.
Funding Goals
TO RENOVATE EXISTING RESEARCH FACILITIES AND BUILD NEW RESEARCH FACILITIES TO MEET BASIC AND CLINICAL SPACE REQUIREMENTS, LABORATORY SAFETY, BIOHAZARD CONTAINMENT, AND ANIMAL CARE STANDARDS IN ORDER TO SUPPORT THE FACILITY DEMANDS OF NIH RESEARCH PROGRAMS.
Grant Program (CFDA)
Awarding Agency
Place of Performance
Chapel Hill,
North Carolina
27599
United States
Geographic Scope
Single Zip Code
Related Opportunity
University Of North Carolina At Chapel Hill was awarded
UNC BSL3 Core Facility: Pandemic Response & Research Expansion
Project Grant C06OD036029
worth $7,916,788
from the National Institute of Allergy and Infectious Diseases in September 2023 with work to be completed primarily in Chapel Hill North Carolina United States.
The grant
has a duration of 4 years 8 months and
was awarded through assistance program 93.352 Construction Support.
The Project Grant was awarded through grant opportunity Biomedical Research Facilities (C06 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 11/20/24
Period of Performance
9/6/23
Start Date
5/31/28
End Date
Funding Split
$7.9M
Federal Obligation
$0.0
Non-Federal Obligation
$7.9M
Total Obligated
Activity Timeline
Transaction History
Modifications to C06OD036029
Additional Detail
Award ID FAIN
C06OD036029
SAI Number
C06OD036029-2896191243
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75AGNA NIH AGGREGATE FINANCIAL ASSISTANCE DATA AWARDING OFFICE
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
D3LHU66KBLD5
Awardee CAGE
4B856
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $7,916,788 | 100% |
Modified: 11/20/24